Radioembolization for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a targeted radiation treatment (radioembolization) given through a artery into the brain for glioblastoma that has come back after standard therapy. It may help people whose tumor is in a single, accessible area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have IDH-wildtype glioblastoma that has already been treated with radiation and chemotherapy
- Your tumor must be a single spot no larger than 6 cm, located where doctors can deliver the treatment through a small tube (catheter) in an artery
- You must have stable neurological symptoms and be able to care for yourself (ECOG score 0-2)
- Your blood counts, kidney, liver, and clotting function must be within certain ranges
- You cannot have had certain prior treatments like VEGF inhibitors or re-radiation, and no other cancer treatments within 28 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.